SCHEINBERG DAVID A 4/A
4/A · SELLAS Life Sciences Group, Inc. · Filed Mar 16, 2018
Insider Transaction Report
Form 4/AAmended
SCHEINBERG DAVID A
Director
Transactions
- Award
Common Stock
2017-12-29+9,107→ 9,107 total
Footnotes (2)
- [F1]In connection with the merger of SELLAS Life Sciences Group, Ltd ("SELLAS") and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"), outstanding restricted stock units ("RSUs") to be settled in SELLAS common shares were assumed by the Issuer and will be settled in shares of the Issuer's common stock based on the following exchange ratio: 43.9972 shares of the Issuer's common stock for each common share of SELLAS.
- [F2]Represents shares issuable upon vesting of RSUs. The RSUs are subject to, and to vest must satisfy, both (a) performance-based vesting restrictions (the RSUs will satisfy the performance-based vesting restrictions upon a liquidity event as defined in the award agreement) and (b) time-based vesting restrictions (100% of the RSUs satisfied the time-based vesting restrictions on February 27, 2018). The Merger did not constitute a liquidity event for the performance-based vesting restrictions.